60693-33-6

Usage

Uses

Used in Pharmaceutical Industry:
4-Succinimidobenzoic acid is used as an intermediate in the synthesis of ciprofibrate, a lipid-regulating drug, for the treatment of dyslipidemia and related conditions.
Used in Agrochemical Industry:
4-Succinimidobenzoic acid is used as an intermediate in the synthesis of various agrochemicals, contributing to the development of effective pest control and crop protection solutions.
Used in Peptide-based Drug Synthesis:
4-Succinimidobenzoic acid is used as a coupling agent in the synthesis of peptide-based drugs, facilitating the formation of peptide bonds and enhancing the efficiency of drug production.
Used in Protein and Peptide Analysis:
4-Succinimidobenzoic acid is used as a fluorescent probe for the determination of proteins and peptides, enabling researchers to study their structure, function, and interactions with other molecules.
Overall, 4-Succinimidobenzoic acid has potential applications in the medical, pharmaceutical, and chemical industries due to its versatile properties and uses.

InChI:InChI=1/C11H9NO4/c13-9-5-6-10(14)12(9)8-3-1-7(2-4-8)11(15)16/h1-4H,5-6H2,(H,15,16)/p-1

Upstream product

• 108-30-5 succinic acid anhydride 
• 150-13-0 4-amino-benzoic acid 
• 110-15-6 succinic acid 
• 76475-62-2 4-(2-carboxyethylcarboxamido)benzoic acid 

Downstream Products

• 65592-93-0 chloroanhydride of 4-succinimidobenzoic acid 
• 363603-29-6 4-(5-acetyl-1,3-dioxo-3,3a,4,5,10,10a-hexahydro-1H-pyrrolo[3,4-b]carbazol-2-yl)-benzoic acid 
• 900093-65-4 (4-methoxyphenylcarbamoyl)methyl 4-(2,5-dioxopyrrolidin-1-yl)benzoate 
• 28867-76-7 benzaldehyde benzylidenehydrazone 
• 166388-08-5 N-benzoyl-N¹-(p-N-succinimide benzoyl)hydrazine 

Relevant academic research and scientific papers

Multitargeted Compounds Derived from (2,5-Dioxopyrrolidin-1-yl)(phenyl)-Acetamides as Candidates for Effective Anticonvulsant and Antinociceptive Agents

We developed a focused set of original hybrid pyrrolidine-2,5-dione derivatives with potent anticonvulsant and antinociceptive properties. These hybrid compounds demonstrated broad-spectrum protective activity in a range of mouse models, such as the maximal electroshock (MES) test, the pentylenetetrazole-induced seizures (scPTZ), and the 6 Hz (32 mA) seizures. Compound 22 showed the most potent anticonvulsant activity (ED50 MES = 23.7 mg/kg, ED50 6 Hz (32 mA) = 22.4 mg/kg, ED50 scPTZ = 59.4 mg/kg). In addition, 22 revealed potent efficacy in the formalin-induced tonic pain. These in vivo activities of 22 are likely mediated by several targets and may result from the inhibition of central sodium/calcium currents and transient receptor potential vanilloid 1 (TRPV1) receptor antagonism. Finally, the lead compound 22 revealed drug-like absorption, distribution, metabolism, excretion, toxicity (ADME-Tox) properties in the in vitro assays, making it a potential candidate for further development in epilepsy and neuropathic pain indications.

Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2

A group of cyclic imides (1-10) was designed for evaluation as a selective COX-2 inhibitors and investigated in vivo for their anti-inflammatory activity. Compounds 6a, 6b, 8a, 8b, 9a, 9b, 10a and 10b were proved to be potent COX-2 inhibitors with IC50 range of 0.1-4.0 μM. In vitro COX-1/COX-2 inhibition structure-activity studies identified compound 8a as a highly potent (IC50 = 0.1 μM), and an extremely selective [COX-2 (SI) > 1000] comparable to celecoxib [COX-2 (SI) > 384], COX-2 inhibitor that showed superior anti-inflammatory activity (ED50 = 72.4 mg/kg) relative to diclofenac (ED50 = 114 mg/kg). Molecular modeling was carried out through docking the designed compounds into the COX-2 binding site to predict if these compounds have analogous binding mode to the COX-2 inhibitors. The study showed that the homosulfonamide fragment of 8a inserted deep inside the 2 -pocket of the COX-2 active site, where the SO2NH2 group underwent H-bonding interaction with Gln192(2.95 A?), Phe 518(2.82 A?) and Arg513(2.63 and 2.73 A?). Docking study of the synthesized compound 8a into the active site of COX-2 revealed a similar binding mode to SC-558, a selective COX-2 inhibitor.

Anti-inflammatory activity and PGE2 inhibitory properties of novel phenylcarbamoylmethyl ester-containing compounds

A variety of 4-(un)substituted phenylcarbamoyl methyl ester-containing compounds 3a-d, 5a-d and 7a-d were synthesized via reaction in N,N-dimethylformamide of (un)substituted chloroacetanilides 2a-d with the potassium salts of ibuprofen (1), naproxen (4)

p-Aminobenzoic acid derivatives as acetylcholinesterase inhibitors

Because Alzheimer's disease (AD) is a medical problem characterized by progressive loss of memory and cognition that is associated with a deficient cholinergic system, this work aims to evaluate some p-aminobenzoic acid (PABA) derivatives as acetylcholinesterase inhibitors in vitro, in continuation with our last studies. The assayed compounds are low toxic, simple-structured and low cost.